Pular para o conteúdo principal
Ranking Invest

IMMP - Immutep Limited

Segmento: HealthcareImmutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Análise Ranking Invest

Valuation estimado
-$ 21.25 Mi
Valor de Mercado
$ 59.05 Mi
Desconto (AV)-377.9%
IVR
-0.36A companhia vale -0,36 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-3.40O valuation alternativo equivale a -340% do valor de mercado da companhia.
MLL
-3.40O lucro líquido dos controladores em 16 trimestres equivale a -340% do valor de mercado.
Último Balanço Atualizado: 2T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 172.47 Mi

Dívida Líquida

-$ 72.20 Mi

L4T

-$ 84.37 Mi

MM4T

-1004.20%

Indicadores Básicos

ROE

-48.92%

Índices de Previsibilidade

Receita Líquida

F0.54

Lucro

B0.17

Margem

E1.11

Índices de Tendência

Receita Líquida

D-0.69

Lucro

G-10.86

Margem

D-0.85

Índices de Endividamento

DIV/PAT

-0.42

DIV/L4T

0.86

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.